RT Journal Article
SR Electronic
T1 Spatial inequities in access to medications for treatment of opioid use disorder highlight scarcity of methadone providers under counterfactual scenarios
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.12.23289915
DO 10.1101/2023.05.12.23289915
A1 Tatara, Eric
A1 Lin, Qinyun
A1 Ozik, Jonathan
A1 Kolak, Marynia
A1 Collier, Nicholson
A1 Halpern, Dylan
A1 Anselin, Luc
A1 Dahari, Harel
A1 Boodram, Basmattee
A1 Schneider, John
YR 2023
UL http://medrxiv.org/content/early/2023/11/08/2023.05.12.23289915.abstract
AB Access to treatment and medication for opioid use disorder (MOUD) is essential in reducing opioid use and associated behavioral risks, such as syringe sharing among persons who inject drugs (PWID). Syringe sharing among PWID carries high risk of transmission of serious infections such as hepatitis C and HIV. MOUD resources, such as methadone provider clinics, however, are often unavailable to PWID due to barriers like long travel distance to the nearest methadone provider and the required frequency of clinic visits. The goal of this study is to examine the uncertainty in the effects of travel distance in initiating and continuing methadone treatment and how these interact with different spatial distributions of methadone providers to impact co-injection (syringe sharing) risks. A baseline scenario of spatial access was established using the existing locations of methadone providers in a geographical area of metropolitan Chicago, Illinois, USA. Next, different counterfactual scenarios redistributed the locations of methadone providers in this geographic area according to the densities of both the general adult population and according to the PWID population per zip code. We define different reasonable methadone access assumptions as the combinations of short, medium, and long travel distance preferences combined with three urban/suburban travel distance preference. Our modeling results show that when there is a low travel distance preference for accessing methadone providers, distributing providers near areas that have the greatest need (defined by density of PWID) is best at reducing syringe sharing behaviors. However, this strategy also decreases access across suburban locales, posing even greater difficulty in regions with fewer transit options and providers. As such, without an adequate number of providers to give equitable coverage across the region, spatial distribution cannot be optimized to provide equitable access to all PWID. Our study has important implications for increasing interest in methadone as a resurgent treatment for MOUD in the United States and for guiding policy toward improving access to MOUD among PWID.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by the National Institute on Drug Abuse (NIH) grant U2CDA050098 (The Methodology and Advanced Analytics Resource Center), by the National Institute of General Medical Sciences grant R01GM121600, by the National Institute of Allergy and Infectious Diseases (NIH) grant R01AI158666, by the National Institute on Drug Abuse (NIH) grant R01DA043484, and by the U.S. Department of Energy under contract number DE-AC02-06CH11357, and was completed with resources provided by the Laboratory Computing Resource Center at Argonne National Laboratory (Bebop cluster). The research presented in this paper is that of the authors and does not necessarily reflect the position or policy of the National Institute on Drug Abuse or any other organization.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data and code used for running experiments, model fitting, and plotting are available on our GitHub repository at https://github.com/hepcep/hepcep_model.